Latest ARYx Therapeutics Stories
ARYx Therapeutics, a biopharmaceutical company, has completed enrollment in EmbraceAC, a Phase II/III double-blind clinical trial comparing its oral anticoagulation therapy, ATI-5923, against the leading anticoagulant agent, warfarin.
ARYx Therapeutics, a biopharmaceutical company focused on developing a portfolio of potentially safer oral drugs, has appointed David Beier to its board of directors.
- A morbid dread of being buried alive. Also spelled 'taphiphobia'.